BioMerieux, Banyan Biomarkers Partner to Commercialize TBI Test

Jan 19, 2017

NEW YORK (360Dx) – BioMérieux said today it has signed a deal to commercialize Banyan Biomarkers' tests for diagnosing traumatic brain injuries (TBI).

Under the terms of the agreement, BioMérieux will make a $7 million equity investment in Banyan in exchange for rights to commercialize Banyan's TBI tests for global use as in vitro diagnostics on BioMérieux's VIDAS immunoassay platform.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Menu

BioMerieux, Banyan Biomarkers Partner to Commercialize TBI Test

To read the full story....

Breaking News

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

In Brief This Week: Invivoscribe, Todos Medical, Personalis, and More

FDA Approves CD Diagnostics' Test for Prosthetic Joint Infections

FDA Clears InBios International Zika Antibody Test

Beckman Coulter Life Sciences Recalls Hematology Analyzers Due to Risk of Inaccurate Results

Featured White Papers

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Clinical Genomics of NTRK Fusion Detection in Cancer

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

What's Popular?

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

Roche Obtains FDA Clearance for Sexually Transmitted Disease Test

FDA Clears Cepheid, Hologic CT/NG Assays for Extragenital Testing

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

Startup Novel Microdevices Developing Rapid Point-of-Care MDx System for STIs

Sponsorships